Oncologic Emergencies: Recognition and Management of Life-Threatening Complications

Oncologic emergencies are life-threatening complications that can occur in cancer patients, requiring immediate recognition and intervention to prevent morbidity and mortality. These emergencies can be broadly classified into four categories: metabolic, structural, hematologic, and treatment-related complications.

[KEY_CONCEPT] The four most common oncologic emergencies encountered in clinical practice are tumor lysis syndrome (TLS), malignant spinal cord compression (MSCC), hypercalcemia of malignancy (HCM), and superior vena cava syndrome (SVCS).

Epidemiology and Risk Factors:

• TLS occurs most commonly with hematologic malignancies (lymphomas, leukemias) but can occur with solid tumors
• MSCC affects 5-10% of cancer patients, with highest incidence in breast, lung, and prostate cancers
• HCM occurs in 10-30% of cancer patients, most commonly with lung cancer, breast cancer, and multiple myeloma
• SVCS has an incidence of 3-8% in cancer patients, with lung cancer accounting for 65-80% of cases

Pathophysiology Overview:

[HIGH_YIELD] Early recognition is crucial as delays in treatment can result in irreversible neurologic deficits (MSCC), cardiac arrhythmias (TLS), or respiratory failure (SVCS).

Tumor Lysis Syndrome (TLS) Clinical Features:

• Constitutional symptoms: Nausea, vomiting, lethargy, weakness
• Cardiac manifestations: Arrhythmias (hyperkalemia), QT prolongation (hypocalcemia)
• Renal symptoms: Oliguria, acute kidney injury, flank pain
• Neurologic signs: Seizures, muscle cramps, tetany (hypocalcemia)

[CLINICAL_PEARL] The classic pentad of TLS includes hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and acute kidney injury.

Malignant Spinal Cord Compression (MSCC) Presentation:

• Back pain (95% of cases): Often the earliest symptom, may worsen with coughing or Valsalva
• Motor weakness: Progressive weakness, typically bilateral and symmetric
• Sensory deficits: Numbness, tingling, loss of position sense
• Autonomic dysfunction: Urinary retention, bowel incontinence, erectile dysfunction

Hypercalcemia of Malignancy (HCM) Symptoms:

• Neurologic: Confusion, depression, psychosis, coma
• Gastrointestinal: Nausea, vomiting, constipation, abdominal pain
• Renal: Polyuria, polydipsia, nephrogenic diabetes insipidus
• Cardiac: Shortened QT interval, bradycardia, heart block

[HIGH_YIELD] Remember "stones, bones, groans, and psychiatric overtones" for hypercalcemia symptoms.

Superior Vena Cava Syndrome (SVCS) Signs:

• Facial/upper extremity edema: Often worse in morning
• Dyspnea: May worsen when lying flat
• Cough: Often dry and persistent
• Voice changes: Hoarseness due to laryngeal edema
• Visual symptoms: Blurred vision, headache
• Pemberton sign: Facial plethora and dyspnea when arms raised overhead

[CLINICAL_PEARL] SVCS symptoms typically worsen with bending forward or lying flat due to increased venous pressure.

Tumor Lysis Syndrome Diagnostic Criteria:

Laboratory TLS (any 2 of the following within 3 days before or 7 days after chemotherapy):

• Uric acid ≥8 mg/dL or 25% increase from baseline
• Potassium ≥6 mEq/L or 25% increase from baseline
• Phosphorus ≥4.5 mg/dL or 25% increase from baseline
• Calcium ≤7 mg/dL or 25% decrease from baseline

Clinical TLS = Laboratory TLS PLUS:

• Acute kidney injury (creatinine ≥1.5× baseline)
• Cardiac arrhythmia
• Seizure
• Death

MSCC Diagnostic Workup:

Suspected MSCC ↓ Immediate IV dexamethasone 10-16 mg ↓ MRI spine (preferred) or CT myelography ↓ Determine level and extent of compression ↓ Assess neurologic function:

• Ambulatory vs non-ambulatory
• Complete vs incomplete block
• Time since symptom onset

[KEY_CONCEPT] MRI is the gold standard for MSCC diagnosis, showing both bone and soft tissue involvement with high sensitivity (93%) and specificity (97%).

Hypercalcemia Diagnostic Studies:

• Serum calcium (corrected for albumin): Corrected Ca = measured Ca + 0.8 × (4.0 - albumin)
• Ionized calcium: Most accurate measurement
• PTH level: Suppressed in malignancy
• PTHrP: Elevated in 80% of HCM cases
• 25-hydroxyvitamin D: May be elevated in lymphomas

HCM Severity Classification:

SVCS Diagnostic Imaging:

• CT chest with contrast: First-line imaging, shows obstruction level and collaterals
• MRI: Alternative if contrast contraindicated
• Venography: Reserved for intervention planning

[HIGH_YIELD] Tissue diagnosis should not delay treatment in SVCS if patient is symptomatic, but biopsy should be obtained when possible for treatment planning.

Tumor Lysis Syndrome Management Algorithm:

TLS Risk Assessment ↓ High Risk → Prophylaxis: • Allopurinol 300-600 mg/day OR • Rasburicase 0.2 mg/kg IV daily • Aggressive hydration (3-4 L/day) • Monitor electrolytes q6-8h ↓ Established TLS → Treatment: • Rasburicase preferred over allopurinol • Correct hyperkalemia (insulin/glucose, kayexalate) • Phosphate binders for hyperphosphatemia • Calcium gluconate for symptomatic hypocalcemia • Hemodialysis if refractory

[CLINICAL_PEARL] Rasburicase is contraindicated in G6PD deficiency as it can cause severe hemolysis.

MSCC Management Strategy:

Immediate Actions:

1. Dexamethasone 10-16 mg IV (even before imaging)
2. Pain control with opioids as needed
3. Imaging within 24 hours (MRI preferred)

Treatment Options by Clinical Status:

Hypercalcemia Management Protocol:

Acute Treatment (Severe HCM):

1. Volume expansion: Normal saline 200-500 mL/hr (monitor for fluid overload)
2. Bisphosphonates:
   • Zoledronic acid 4 mg IV over 15 minutes (preferred)
   • Pamidronate 60-90 mg IV over 2-4 hours
3. Calcitonin: 4-8 units/kg IM/SC q6-12h (rapid onset, short duration)
4. Severe cases: Consider denosumab 120 mg SC

[HIGH_YIELD] Bisphosphonates take 2-4 days to reach maximum effect, while calcitonin works within hours but has limited duration.

SVCS Management Approach:

SVCS Presentation ↓ Symptom Severity Assessment ↓ Mild-Moderate → Tissue diagnosis first • Bronchoscopy, mediastinoscopy, or • CT-guided biopsy ↓ Severe/Life-threatening → Immediate intervention • High-dose corticosteroids • Radiation therapy (if radiosensitive) • Stenting (mechanical obstruction) • Chemotherapy (if chemosensitive)

SVCS Treatment by Histology:

• Small cell lung cancer: Chemotherapy first-line
• Lymphoma: Chemotherapy or radiation
• Non-small cell lung cancer: Radiation or stenting
• Unknown primary: Empirical radiation while pursuing diagnosis

Tumor Lysis Syndrome Complications:

Acute Complications:

• Cardiac arrhythmias: Hyperkalemia can cause peaked T-waves, widened QRS, asystole
• Seizures: Due to hypocalcemia or metabolic acidosis
• Acute kidney injury: Uric acid nephropathy, calcium phosphate precipitation
• Disseminated intravascular coagulation: Rare but life-threatening

Monitoring Parameters:

• Electrolytes, BUN/creatinine every 6-8 hours initially
• Continuous cardiac monitoring
• Urine output (goal >2 mL/kg/hr)
• Phosphorus-calcium product (goal <60 mg²/dL²)

MSCC Long-term Outcomes:

[KEY_CONCEPT] Functional status at diagnosis is the strongest predictor of neurologic recovery. Patients who are ambulatory at diagnosis have >80% chance of remaining ambulatory, while non-ambulatory patients have <10% chance of regaining ambulation.

Prognostic Factors for MSCC Recovery:

• Time from symptom onset to treatment (<24 hours better prognosis)
• Degree of neurologic deficit at presentation
• Tumor radiosensitivity
• Overall cancer prognosis
• Extent of spinal involvement

Hypercalcemia Monitoring and Prevention:

Monitoring Parameters:

• Serum calcium every 12-24 hours initially
• Renal function (BUN/creatinine)
• Cardiac rhythm monitoring if severe
• Neurologic status assessment

Prevention Strategies:

• Adequate hydration during cancer treatment
• Early bisphosphonate therapy in high-risk patients
• Regular monitoring in susceptible malignancies

SVCS Complications:

Potential Complications:

• Cerebral edema: Due to impaired venous drainage
• Airway compromise: Laryngeal or tracheal edema
• Cardiovascular collapse: Reduced venous return
• Thrombosis: Sluggish blood flow in compressed vessels

[CLINICAL_PEARL] Avoid supine positioning in SVCS patients as this can worsen venous congestion and respiratory symptoms.

Long-term Management:

• Regular imaging to assess response
• Anticoagulation consideration if thrombosis present
• Symptom monitoring and quality of life assessment
• Coordination with oncology for underlying malignancy treatment

Quality of Life Considerations:

• Pain management protocols
• Physical therapy and rehabilitation
• Psychosocial support
• Advanced care planning discussions when appropriate

Tumor Lysis Syndrome Prevention Strategies:

Risk Stratification for TLS Prevention:

[HIGH_YIELD] High-risk patients should receive rasburicase prophylaxis and be monitored in an ICU setting during initial treatment.

Prevention Protocols:

• Pre-treatment hydration: 2-3 L normal saline over 24 hours
• Urine alkalinization (controversial): Sodium bicarbonate to maintain urine pH 7-7.5
• Prophylactic medications initiated 24-48 hours before chemotherapy
• Avoid nephrotoxic medications

MSCC Prevention and Early Detection:

Screening in High-Risk Patients:

• Regular neurologic examinations in patients with vertebral metastases
• Patient education regarding warning signs
• MRI surveillance in asymptomatic patients with epidural disease
• Prophylactic radiation to unstable vertebral lesions

[CLINICAL_PEARL] Patients with breast, lung, prostate, kidney, or myeloma should be counseled about back pain as a warning sign requiring immediate evaluation.

Hypercalcemia Prevention:

Preventive Measures:

• Adequate hydration during hospitalizations
• Bisphosphonate therapy for bone metastases
• Monitoring calcium levels during treatment
• Limiting vitamin D and calcium supplementation
• Regular monitoring in high-risk malignancies

Follow-up Monitoring Schedule:

• Monthly calcium levels in active malignancy
• Bone-specific alkaline phosphatase monitoring
• Renal function assessment every 3-6 months on bisphosphonates

SVCS Prevention:

Risk Reduction Strategies:

• Early diagnosis and treatment of mediastinal masses
• Anticoagulation in high-risk patients
• Central venous catheter management
• Regular imaging in patients with mediastinal involvement

Long-term Outcomes and Prognosis:

TLS Outcomes:

• Mortality rate: 5-10% with appropriate management
• Most survivors have complete recovery of renal function
• Recurrence risk with subsequent chemotherapy cycles

MSCC Prognosis:

• Ambulatory status at diagnosis: 80-90% remain ambulatory
• Non-ambulatory patients: 10-15% regain ambulation
• Median survival varies by primary tumor (3-15 months)

HCM Prognosis:

• Often indicates advanced malignancy
• Median survival: 1-3 months without treatment of underlying cancer
• Response to treatment: 70-90% achieve normocalcemia

SVCS Outcomes:

• Symptom improvement: 60-95% depending on etiology
• Median survival depends on underlying malignancy
• Quality of life generally improves with successful treatment

[KEY_CONCEPT] Early recognition and prompt treatment are crucial for optimal outcomes in all oncologic emergencies, with functional status at presentation being the strongest predictor of recovery in MSCC.